SCHEMBL6918172

SCHEMBL6918172

CC(NC(=O)c1cccc(S(C)(=O)=O)c1)c1cccc(C(=O)NO)c1

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
GAA P10253 2/20 0.64
CA2 P00918 2/20 0.60
KCNQ3 O43525 2/20 0.49
KCNQ2 O43526 2/20 0.49
KCNQ4 P56696 1/20 0.49
KCNQ5 Q9NR82 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HDAC8 Q9BY41 4/20 0.48
HDAC6 Q9UBN7 4/20 0.48
HSD17B10 Q99714 1/20 0.48
HDAC2 Q92769 1/20 0.47
KAT6A Q92794 1/20 0.46
IKBKB O14920 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14507863 0.81 ALDH1A1 (0.69) ALDH1A1GAACA2SMN1; SMN2HSD17B10
SCHEMBL12279819 0.80 ALDH1A1 (0.57) ALDH1A1GAACA2SMN1; SMN2HDAC8
SCHEMBL2410752 0.79 HDAC6 (0.56) ALDH1A1GAACA2SMN1; SMN2HDAC8
SCHEMBL2409587 0.78 ALDH1A1 (0.56) ALDH1A1GAACA2SMN1; SMN2HDAC8
SCHEMBL2412896 0.78 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HDAC8
SCHEMBL12280060 0.78 NR1H4 (0.59) ALDH1A1CA2SMN1; SMN2HDAC8HDAC6
SCHEMBL2409529 0.78 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HDAC8
SCHEMBL2406385 0.78 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HDAC8
SCHEMBL2407090 0.77 CA1 (0.59) ALDH1A1GAACA2
SCHEMBL2409579 0.77 NPSR1 (0.56) ALDH1A1CA2SMN1; SMN2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 ALDH1A1 1696/4885GAA 252/4885CA2 308/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 ALDH1A1 1696/4885GAA 252/4885CA2 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.